Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1027757-13-6 | MDL No. : | MFCD03001334 |
Formula : | C19H23BO3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | OYMQYMSYMNEKLI-UHFFFAOYSA-N |
M.W : | 310.20 | Pubchem ID : | 3525007 |
Synonyms : |
|
Num. heavy atoms : | 23 |
Num. arom. heavy atoms : | 12 |
Fraction Csp3 : | 0.37 |
Num. rotatable bonds : | 4 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 93.9 |
TPSA : | 27.69 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | Yes |
CYP3A4 inhibitor : | Yes |
Log Kp (skin permeation) : | -5.09 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 4.37 |
Log Po/w (WLOGP) : | 3.41 |
Log Po/w (MLOGP) : | 2.63 |
Log Po/w (SILICOS-IT) : | 3.36 |
Consensus Log Po/w : | 2.75 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -4.64 |
Solubility : | 0.00713 mg/ml ; 0.000023 mol/l |
Class : | Moderately soluble |
Log S (Ali) : | -4.67 |
Solubility : | 0.00667 mg/ml ; 0.0000215 mol/l |
Class : | Moderately soluble |
Log S (SILICOS-IT) : | -6.64 |
Solubility : | 0.0000706 mg/ml ; 0.000000228 mol/l |
Class : | Poorly soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 3.31 |
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
23% | With tetrakis(triphenylphosphine) palladium(0); potassium carbonate In toluene at 80℃; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
98% | With trifluoroacetic acid at 20℃; for 3h; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
46% | With [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(ll) dichloride; potassium carbonate In isopropyl alcohol at 110℃; for 0.5h; Microwave irradiation; | 71 Example 71 : 7-(2-(benzyloxy)phenyl)-5-methyl-2-((4-(methylsulphonyl)piperazin-1- yl)methyl)thienor3,2-clpyridin-4(5H)-one To a solution of 7-bromo-5-methyl-2-((4-(methylsulphonyl)piperazin-1-yl)methyl)thieno[3,2-c]pyridin- 4(5H)-one (for a preparation see Intermediate 69, 150 mg, 0.357 mmol) and 2-(2- (benzyloxy)phenyl)-4, 4, 5, 5-tetra methyl- 1 ,3,2-dioxaborolane (166 mg, 0.535 mmol) in isopropanol (5 ml.) were successively added potassium carbonate (0.892 ml_, 1.784 mmol) and PEPPSI (24.25 mg, 0.036 mmol). The resulting mixture was heated at 1 10 °C in the microwave for 30 min, whereupon the reaction mixture was allowed to cool down to rt and was concentrated in vacuo. The crude residue was partitioned between EtOAc and a saturated aqueous solution of sodium bicarbonate. The phases were separated, the aqueous phase was extracted 3 times with EtOAc and the combined organic layers were washed with brine, dried over MgSC , filtered and concentrated in vacuo. The residue was purified via MDAP. The appropriate fractions were combined and concentrated in vacuo to give 7-(2-(benzyloxy)phenyl)-5-methyl-2-((4-(methylsulphonyl)piperazin-1- yl)methyl)thieno[3,2-c]pyridin-4(5H)-one (85 mg, 46% yield) as a white solid. LCMS (2 min, Formic Acid): Rt = 0.89 min, MH+ = 524. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Multi-step reaction with 2 steps 1.1: formic acid; sodium cyanoborohydride / methanol / 16 h / 0 - 20 °C / pH 3 - 4 / Inert atmosphere 1.2: 0 °C / Inert atmosphere 2.1: bis(1,5-cyclooctadiene)nickel(0); 1,3-dicyclohexyl-1H-imidazol-3-ium chloride; potassium <i>tert</i>-butylate / toluene; 2-ethoxy-ethanol / 24 h / 50 °C / Schlenk technique; Inert atmosphere |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
55% | With bis(1,5-cyclooctadiene)nickel(0); potassium <i>tert</i>-butylate; 1,3-dicyclohexyl-1H-imidazol-3-ium chloride In 2-ethoxy-ethanol; toluene at 50℃; for 24h; Schlenk technique; Inert atmosphere; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With C26H30FeNP; palladium diacetate; sodium phosphate In 1,4-dioxane at 40 - 100℃; for 100h; Inert atmosphere; Overall yield = 80 %; Optical yield = 86 %ee; | 12 Example 12: Preparation of Compound 12 Under nitrogen protection,(0.25 mmol) of (1-bromo-2-naphthyl) -diphenylphosphine oxide,62 mg (0.5 mmol) of aryl boronate,159 mg (0.75 mmol) of Na3PO4,5.65 mg (0.012 mmol) of ligand L4,4.58 mg (0.005 mmol) of Pd (OAc) 2 was added to the reaction tube.3 mL of oxygen-free dioxane as solvent,40-100 ° C for 100 hours.The reaction system is filtered to remove insoluble matter, concentrated, and the crude product is separated and purified by a silica gel column to obtain a pale yellow solid product. Ml, tR = 7.69 min, HPLC: m / z: 80%, enantioselectivity: 86% ee (high performance liquid chromatography, ChiralcelAD-H column, 25C, n-hexane: isopropanol = 75:25, 1.0 mL / 12.20 min) |
[ 1204580-85-7 ]
2-(2-(Benzyloxy)-5-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.99
[ 1626407-70-2 ]
2-(4-(Benzyloxy)-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.99
[ 1626407-70-2 ]
2-(4-(Benzyloxy)-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.99
[ 1059066-01-1 ]
2-{4-[(4-Methoxyphenyl)methoxy]phenyl}-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.95
[ 754226-40-9 ]
2-(4-(Benzyloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.95
[ 1204580-85-7 ]
2-(2-(Benzyloxy)-5-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.99
[ 1626407-70-2 ]
2-(4-(Benzyloxy)-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.99
[ 1059066-01-1 ]
2-{4-[(4-Methoxyphenyl)methoxy]phenyl}-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.95
[ 754226-40-9 ]
2-(4-(Benzyloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.95
[ 1204580-85-7 ]
2-(2-(Benzyloxy)-5-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.99
[ 1626407-70-2 ]
2-(4-(Benzyloxy)-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.99
[ 1059066-01-1 ]
2-{4-[(4-Methoxyphenyl)methoxy]phenyl}-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.95
[ 754226-40-9 ]
2-(4-(Benzyloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.95
[ 1204580-85-7 ]
2-(2-(Benzyloxy)-5-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.99
[ 2121511-63-3 ]
2-(2-(Benzyloxy)-4-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.99
[ 1626407-70-2 ]
2-(4-(Benzyloxy)-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.99
[ 2121514-58-5 ]
2-(2-(Benzyloxy)-4,5-dimethylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.97
[ 2121514-22-3 ]
2-(3-(Benzyloxy)-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
Similarity: 0.96